Rapamycin Promotes Expansion of Functional CD4+CD25+FOXP3+ Regulatory T Cells of Both Healthy Subjects and Type 1 Diabetic Patients1

CD4+CD25+FOXP3+ T regulatory cells (Tregs) are pivotal for the induction and maintenance of peripheral tolerance in both mice and humans. Rapamycin has been shown to promote tolerance in experimental models and to favor CD4+CD25+ Treg-dependent suppression. We recently reported that rapamycin allows in vitro expansion of murine CD4+CD25+FoxP3+ Tregs, which preserve their suppressive function. In the current study, we show that activation of human CD4+ T cells from healthy subjects in the presence of rapamycin leads to growth of CD4+CD25+FOXP3+ Tregs and to selective depletion of CD4+CD25− T effector cells, which are highly sensitive to the antiproliferative effect of the compound. The rapamycin-expanded Tregs suppress proliferation of both syngeneic and allogeneic CD4+ and CD8+ T cells. Interestingly, rapamycin promotes expansion of functional CD4+CD25+FOXP3+ Tregs also in type 1 diabetic patients, in whom a defect in freshly isolated CD4+CD25+ Tregs has been reported. The capacity of rapamycin to allow growth of functional CD4+CD25+FOXP3+ Tregs, but also to deplete T effector cells, can be exploited for the design of novel and safe in vitro protocols for cellular immunotherapy in T cell-mediated diseases.

[1]  M. Battaglia,et al.  Erratum: Interleukin-10- secreting type 1 regulatory T cells in rodents and humans (Immunological Reviews (2006) 212, (28-50)) , 2006 .

[2]  J. Ritz,et al.  IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. , 2006, Blood.

[3]  Katharina Fleischhauer,et al.  Interleukin‐10‐secreting type 1 regulatory T cells in rodents and humans , 2006, Immunological reviews.

[4]  D. Valmori,et al.  Rapamycin-Mediated Enrichment of T Cells with Regulatory Activity in Stimulated CD4+ T Cell Cultures Is Not Due to the Selective Expansion of Naturally Occurring Regulatory T Cells but to the Induction of Regulatory Functions in Conventional CD4+ T Cells1 , 2006, The Journal of Immunology.

[5]  W. Selby,et al.  Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells , 2006, The Journal of experimental medicine.

[6]  T. Gingeras,et al.  CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells , 2006, The Journal of experimental medicine.

[7]  Christopher H Contag,et al.  Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. , 2006, Blood.

[8]  S. Ziegler,et al.  Defective regulatory and effector T cell functions in patients with FOXP3 mutations. , 2006, The Journal of clinical investigation.

[9]  E. Bonifacio,et al.  Induction of Tolerance in Type 1 Diabetes via Both CD4+CD25+ T Regulatory Cells and T Regulatory Type 1 Cells , 2006, Diabetes.

[10]  S. Ziegler.  FOXP3: of mice and men. , 2006, Annual review of immunology.

[11]  I. T. Ten Berge,et al.  Rapamycin Does Not Induce Anergy but Inhibits Expansion and Differentiation of Alloreactive Human T Cells , 2006, Transplantation.

[12]  H. Koenen,et al.  Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. , 2006, Blood.

[13]  S. Ziegler,et al.  The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. , 2005, The Journal of clinical investigation.

[14]  M. Battaglia,et al.  Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. , 2005, Blood.

[15]  A. Rudensky,et al.  Regulation of immunity by self-reactive T cells , 2005, Nature.

[16]  M. Atkinson,et al.  Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. , 2005, Diabetes.

[17]  S. Sakaguchi.  Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self , 2005, Nature Immunology.

[18]  S. Ziegler,et al.  De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4+CD25- cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  P. Gottlieb,et al.  CD4+CD25high regulatory T cells in human autoimmune diabetes. , 2005, Journal of autoimmunity.

[20]  P. Hammerman,et al.  The Pim kinases control rapamycin-resistant T cell survival and activation , 2005, The Journal of experimental medicine.

[21]  A. Saoudi,et al.  Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. , 2005, Blood.

[22]  M. Peakman,et al.  Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. , 2005, Diabetes.

[23]  T. Malek,et al.  Tolerance, not immunity, crucially depends on IL-2 , 2004, Nature Reviews Immunology.

[24]  B. Levine,et al.  In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. , 2004, Blood.

[25]  R. Andreesen,et al.  Large scale in vitro expansion of polyclonal human CD4+CD25high regulatory T cells , 2004, Cancer Cell International.

[26]  H. Lorenz,et al.  Defective Suppressor Function of Human CD4+ CD25+ Regulatory T Cells in Autoimmune Polyglandular Syndrome Type II , 2004, The Journal of experimental medicine.

[27]  M. Farrar,et al.  Distinct IL-2 Receptor Signaling Pattern in CD4+CD25+ Regulatory T Cells1 , 2004, The Journal of Immunology.

[28]  Clare Baecher-Allan,et al.  Loss of Functional Suppression by CD4+CD25+ Regulatory T Cells in Patients with Multiple Sclerosis , 2004, The Journal of experimental medicine.

[29]  C. Baecher-Allan,et al.  Human CD4+CD25+ regulatory T cells. , 2004, Seminars in immunology.

[30]  Manuela Battaglia,et al.  Human CD25+CD4+ T Suppressor Cell Clones Produce Transforming Growth Factor β, but not Interleukin 10, and Are Distinct from Type 1 T Regulatory Cells , 2002, The Journal of experimental medicine.

[31]  C. Fathman,et al.  The Subpopulation of CD4+CD25+ Splenocytes That Delays Adoptive Transfer of Diabetes Expresses L-Selectin and High Levels of CCR71 , 2002, The Journal of Immunology.

[32]  Svetlana Ten,et al.  Multiple immuno-regulatory defects in type-1 diabetes. , 2002, The Journal of clinical investigation.

[33]  G. Freeman,et al.  CD4+CD25high Regulatory Cells in Human Peripheral Blood1 , 2001, The Journal of Immunology.

[34]  G. Schuler,et al.  Ex Vivo Isolation and Characterization of Cd4+Cd25+ T Cells with Regulatory Properties from Human Blood , 2001, The Journal of experimental medicine.

[35]  A. Enk,et al.  Identification and Functional Characterization of Human Cd4+Cd25+ T Cells with Regulatory Properties Isolated from Peripheral Blood , 2001, The Journal of experimental medicine.

[36]  M. Roncarolo,et al.  Human Cd25+Cd4+ T Regulatory Cells Suppress Naive and Memory T Cell Proliferation and Can Be Expanded in Vitro without Loss of Function , 2001, The Journal of experimental medicine.

[37]  E. Wolf,et al.  CCR7 Coordinates the Primary Immune Response by Establishing Functional Microenvironments in Secondary Lymphoid Organs , 1999, Cell.

[38]  W. Waldhäusl,et al.  Increased CD69 and human leukocyte antigen-DR expression on T lymphocytes in insulin-dependent diabetes mellitus of long standing. , 1998, The Journal of clinical endocrinology and metabolism.

[39]  R. Abraham,et al.  Immunopharmacology of rapamycin. , 1996, Annual review of immunology.

[40]  F. Cerutti,et al.  Interleukin-2 production and interleukin-2 receptor expression in children with newly diagnosed diabetes. , 1988, Clinical immunology and immunopathology.